{"id":35128,"date":"2026-04-13T14:10:33","date_gmt":"2026-04-13T14:10:33","guid":{"rendered":"https:\/\/lamarr-institute.org\/publication\/categorization-of-protein-kinases-by-combining-data-from-cell-biology-and-medicinal-chemistry-enables-further-evaluation-and-differentiation-of-the-understudied-kinome\/"},"modified":"2026-06-08T13:17:36","modified_gmt":"2026-06-08T13:17:36","slug":"categorization-of-protein-kinases-by-combining-data-from-cell-biology-and-medicinal-chemistry-enables-further-evaluation-and-differentiation-of-the-understudied-kinome","status":"publish","type":"publication","link":"https:\/\/lamarr-institute.org\/de\/publication\/categorization-of-protein-kinases-by-combining-data-from-cell-biology-and-medicinal-chemistry-enables-further-evaluation-and-differentiation-of-the-understudied-kinome\/","title":{"rendered":"Categorization of Protein Kinases by Combining Data from Cell Biology and Medicinal Chemistry Enables Further Evaluation and Differentiation of the Understudied Kinome"},"content":{"rendered":"<p>Protein kinases ({PKs}) are among the most intensely investigated drug targets. Small molecular {PK} inhibitors ({PKIs}) are preferred agents for therapeutic intervention. Late in 2025, the 100th {PKI} reached drug approval by the U.S. Food and Drug Administration. However, current {PKI} drugs are directed against a limited number of primary {PK} targets. Thus, numerous {PKs} comprising the human kinome remain available as potential pharmaceutical targets. In 2019, the U.S. National Institutes of Health reported 162 understudied human kinases including 155 {PKs} (and seven lipid kinases), referred to as dark kinases or the dark kinome. These kinases were identified primarily considering limited functional information and the lack of detection reagents. Herein, we report a new categorization of the human kinome based on publicly available biological and {PKI} data. The unified categorization integrates biological and chemical exploration of {PKs}, introduces new {PK} categories for target evaluation, and defines the understudied kinome.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Protein kinases ({PKs}) are among the most intensely investigated drug targets. Small molecular {PK} inhibitors ({PKIs}) are preferred agents for therapeutic intervention. Late in 2025, the 100th {PKI} reached drug approval by the U.S. Food and Drug Administration. However, current {PKI} drugs are directed against a limited number of primary {PK} targets. Thus, numerous {PKs} comprising the human kinome remain available as potential pharmaceutical targets. In 2019, the U.S. National [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":0,"template":"","meta":{"_acf_changed":false,"footnotes":""},"publication-type":[30],"class_list":["post-35128","publication","type-publication","status-publish","hentry","publication-type-article"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/lamarr-institute.org\/de\/wp-json\/wp\/v2\/publication\/35128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lamarr-institute.org\/de\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/lamarr-institute.org\/de\/wp-json\/wp\/v2\/types\/publication"}],"author":[{"embeddable":true,"href":"https:\/\/lamarr-institute.org\/de\/wp-json\/wp\/v2\/users\/12"}],"version-history":[{"count":0,"href":"https:\/\/lamarr-institute.org\/de\/wp-json\/wp\/v2\/publication\/35128\/revisions"}],"wp:attachment":[{"href":"https:\/\/lamarr-institute.org\/de\/wp-json\/wp\/v2\/media?parent=35128"}],"wp:term":[{"taxonomy":"publication-type","embeddable":true,"href":"https:\/\/lamarr-institute.org\/de\/wp-json\/wp\/v2\/publication-type?post=35128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}